Skip to main content

Positron Corporation Secures Multi-Unit Sale of PET-CT Scanners to Leading Cardiology Group

Written by Customer Service on . Posted in Public Companies.

Niagara Falls, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners to a nationally recognized nuclear cardiology group specializing in advanced cardiovascular diagnostics and interventional care.

This substantial multi-unit order underscores the growing demand for Positron’s next-generation PET-CT imaging solutions, which combine cutting-edge hardware with comprehensive clinical, technical, and training support. Positron’s PET-CT scanners are quickly becoming the preferred solution for practices seeking superior performance, value, and efficiency in cardiac PET imaging.

Engineered to optimize both clinical outcomes and operational efficiency, Positron’s PET-CT scanners deliver high-resolution anatomic and functional imaging for both cardiac and oncology applications. Key features include a 72 cm wide-bore gantry for enhanced patient comfort, high-sensitivity detectors that reduce radiation exposure, and a compact design, the smallest and lightest in its class, making it ideal for diverse clinical environments.

Positron’s advanced data acquisition capabilities deliver fast, high precision imaging, enhancing diagnostic confidence while expanding the range of studies physicians can perform, from myocardial perfusion to tumor detection and neurological assessments.

Adel Abdullah, President of Positron, commented, “We are proud to partner with one of the nation’s most respected nuclear cardiology medical groups. This milestone reflects the growing recognition of Positron’s advanced PET imaging systems and full-service clinical support.” Mr. Abdullah continued, “At Positron, our mission is to transform cardiac PET imaging by delivering scalable, high-performance solutions that not only meet today’s clinical needs but also prepare healthcare providers for the future of precision diagnostics.”

About Positron Corporation

Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.

Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.

Positron’s Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine. 

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.  

Please visit the Company’s website at: www.positron.com

Forward-Looking Statements                             
This press release contains statements which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.

FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com

Investor Relations Contact:
Skyline Corporate Communications Group, LLC
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
info@skylineccg.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.